Advertisement

Topics

Can the Microbiome Deliver? A Proof-of-Concept Engineered E. coli PKU Therapeutic.

08:00 EDT 10th April 2019 | BioPortfolio

Summary of "Can the Microbiome Deliver? A Proof-of-Concept Engineered E. coli PKU Therapeutic."

Phenylketonuria (PKU) is a rare genetic disorder that causes phenylalanine toxicity in the brain. Two studies, Crook et al. (2019), in this issue of Cell Host & Microbe, and Isabella et al. (2018), employ synthetic biology to develop a live bacterial therapeutic to treat PKU and potentially other metabolic diseases.

Affiliation

Journal Details

This article was published in the following journal.

Name: Cell host & microbe
ISSN: 1934-6069
Pages: 473-474

Links

DeepDyve research library

PubMed Articles [11427 Associated PubMed Articles listed on BioPortfolio]

Gut microbiome and cancer immunotherapy.

Microbiome is becoming crucial in that the balance between human health and disease can be mediated by the gut microbiome. The gut microbiome can modulate the host immune system both locally and syste...

Expanded synthetic small regulatory RNA expression platforms for rapid and multiplex gene expression knockdown.

Synthetic small regulatory RNA (sRNA) can efficiently downregulate target gene expression at translational level in metabolic engineering, but cannot be used in engineered strain already having incomp...

Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study.

The aim of this proof of concept, prospective, randomized pilot trial was to investigate the effects of extracorporeal cytokine removal (CytoSorb®) applied as a standalone treatment in patients with ...

Promoting Independent Mobility-related Physical ACTivity (IMPACT) in an inpatient stroke rehabilitation unit: a proof-of-concept evaluation of self-management intervention.

To establish proof-of-concept of a novel rehabilitation self-management program that aims to optimize walking recovery after stroke through engaging patients in independent walking-related practice ou...

Engineering Escherichia coli as a platform for the in vivo synthesis of prenylated aromatics.

Prenylated aromatics (PAs) are an important class of natural products with valuable pharmaceutical applications. To address current limitations of their sourcing from plants, here, we present a microb...

Clinical Trials [5008 Associated Clinical Trials listed on BioPortfolio]

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

The purpose of this study is to measure the therapeutic potential of Escherichia coli (E. coli) and yeast ribosomal Ribonucleic acid (RNA) fragments to maintain the production of platelets...

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Phase IIa, open clinical trial, pilot, single arm and proof of concept.

Probiotics and the Gut Microbiome in Obese Hispanic Youth

This study will recruit 40 obese Hispanic youth (12 - 18 years of age who are greater than or equal to Tanner stage 4) from hospitals, clinics, and community centers. Participants will be ...

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

This study is a proof of concept study to confirm in a standardized manner the therapeutic efficacy of roflumilast in type 2 diabetes mellitus patients.

Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients

The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) pat...

Medical and Biotech [MESH] Definitions

An empirical investigation which pertains to the development of prototypes or models that demonstrate the feasibility of novel concepts, ideas, principles, schema or their practical application.

Strains of ESCHERICHIA COLI that are a subgroup of SHIGA-TOXIGENIC ESCHERICHIA COLI. They cause non-bloody and bloody DIARRHEA; HEMOLYTIC UREMIC SYNDROME; and hemorrhagic COLITIS. An important member of this subgroup is ESCHERICHIA COLI O157-H7.

Strains of Escherichia coli that possess virulence traits which allow them to invade, colonize, and induce disease in tissues outside of the GASTROINTESTINAL TRACT. They are a cause of URINARY TRACT INFECTIONS (UROPATHOGENIC ESCHERICHIA COLI); neonatal MENINGITIS; SEPSIS; PNEUMONIA; and SURGICAL WOUND INFECTION.

An enterohemorrhagic Escherichia coli of the O subfamily that can cause severe FOODBORNE DISEASE. The H4 serotype strain produces SHIGA TOXINS and has been linked to human disease outbreaks, including some cases of HEMOLYTIC-UREMIC SYNDROME, resulting from contamination of foods by feces containing E. coli O104.

A verocytotoxin-producing serogroup belonging to the O subfamily of Escherichia coli which has been shown to cause severe food-borne disease. A strain from this serogroup, serotype H7, which produces SHIGA TOXINS, has been linked to human disease outbreaks resulting from contamination of foods by E. coli O157 from bovine origin.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article